Medscape InDiscussion: Crohn's Disease

By: Medscape
  • Summary

  • Join Dr Peter Higgins for Medscape InDiscussion: Crohn's Disease, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/967620). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.
    Copyright 2022, Medscape
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Managing Crohn's Disease After Surgery
    Sep 22 2022

    Drs Peter Higgins and Michael Chiorean discuss risk stratification, monitoring, and treatment of Crohn's disease after surgery.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/967627). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Laparoscopic Ileocaecal Resection Versus Infliximab for Terminal Ileitis in Crohn's Disease: Retrospective Long-term Follow-up of the LIR!C Trial https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30117-5/fulltext

    Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection https://www.gastrojournal.org/article/S0016-5085(16)00293-6/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F

    Crohn's Disease Management After Intestinal Resection: A Randomised Trial https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(14)61908-5.pdf

    Controlled Trial of Metronidazole Treatment for Prevention of Crohn's Recurrence After Ileal Resection https://www.gastrojournal.org/article/0016-5085(95)90121-3/pdf?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F

    Metronidazole https://reference.medscape.com/drug/flagyl-metronidazole-342566

    Nitroimidazoles https://reference.medscape.com/drugs/nitroimidazoles

    Ciprofloxacin for the Prevention of Postoperative Recurrence in Patients With Crohn's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Study https://academic.oup.com/ibdjournal/article/19/5/1073/4603177?login=true

    Postoperative Therapy With Infliximab Prevents Long-term Crohn's Disease Recurrence https://www.cghjournal.org/article/S1542-3565(14)00053-6/fulltext

    Mesalamine https://reference.medscape.com/drug/asacol-hd-pentasa-mesalamine-342074

    Infliximab https://reference.medscape.com/drug/remicade-inflectra-infliximab-343202

    Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease https://www.nejm.org/doi/full/10.1056/nejmoa0904492

    Adalimumab https://reference.medscape.com/drug/amjevita-humira-adalimumab-343187

    What Is the Role of Fecal Calprotectin Levels in the Diagnosis of Inflammatory Bowel Disease (IBD)? https://www.medscape.com/answers/179037-54913/what-is-the-role-of-fecal-calprotectin-levels-in-the-diagnosis-of-inflammatory-bowel-disease-ibd

    P115 Monitoring Faecal Calprotectin at 3 Months Post-Surgery Is Useful to Predict Further Postoperative Endoscopic Recurrence in Crohn's Disease https://academic.oup.com/ecco-jcc/article/13/Supplement_1/S145/5300800

    Ustekinumab https://reference.medscape.com/drug/stelara-ustekinumab-345050

    Show more Show less
    25 mins
  • Breaking the Therapeutic Ceiling in Crohn's Disease
    Aug 23 2022

    Drs Peter Higgins and Bram Verstockt discuss breaking the therapeutic ceiling in Crohn's disease and the differential effectiveness of therapies and phenotypes in identifying responses to treatment.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/967626). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Crohn's Disease https://emedicine.medscape.com/article/172940-overview

    A Blood-Based Prognostic Biomarker in IBD https://gut.bmj.com/content/68/8/1386

    Role of the IL23/IL17 Pathway in Crohn's Disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042267/

    A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (VEGA) https://clinicaltrials.gov/ct2/show/NCT03662542

    Results of Novel Clinical Study Show Adults With Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks With Guselkumab and Golimumab Combination Therapy Versus Either Monotherapy Alone https://www.prnewswire.com/news-releases/results-of-novel-clinical-study-show-adults-with-moderately-to-severely-active-ulcerative-colitis-achieved-higher-rates-of-clinical-response-clinical-remission-and-endoscopic-improvement-at-12-weeks-with-guselkumab-and-golimumab-301486054.html

    Digestive Disease Week 2022 https://ddw.org/

    Triple Combination Therapy in High Risk Crohn's Disease (CD) https://clinicaltrials.gov/ct2/show/NCT02764762

    Anti-TNF and Crohn's Disease: When Should We Stop? http://www.eurekaselect.com/article/15866

    Show more Show less
    25 mins
  • Anti–interleukin-23 Medications and Durable Remission for Patients With Crohn's Disease
    Jul 21 2022

    Drs Peter Higgins and Raja Atreya discuss the phenomenon of durable drug free remission in a subset of patients with Crohn's disease and the future of intermittent induction and sequencing of therapies.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/967625). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(21)03725-2

    Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684487/

    Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial https://linkinghub.elsevier.com/retrieve/pii/S1542-3565(21)00203-2

    Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease https://www.nejm.org/doi/full/10.1056/NEJMoa1602773

    Risankizumab as Induction Therapy for Crohn's Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00467-6/fulltext

    Risankizumab as Maintenance Therapy for Moderately to Severely Active Crohn's Disease: Results from the Multicentre, Randomised, Double-Blind, Placebo-Controlled, Withdrawal Phase 3 FORTIFY Maintenance Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00466-4/fulltext

    A37 Efficacy and Safety of Risankizumab as Maintenance Therapy in Patients With Crohn's Disease: 52 Week Results From the Phase 3 Fortify Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859234/

    Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846404

    Expansion of IL-23 Receptor Bearing TNFR2+ T Cells Is Associated With Molecular Resistance to Anti-TNF Therapy in Crohn's Disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580782/

    Comparative Efficacy and Safety of Biologic Therapies for Moderate-to-Severe Crohn's Disease: A Systematic Review and Network Meta-analysis https://linkinghub.elsevier.com/retrieve/pii/S2468-1253(21)00312-5

    European Crohn's and Colitis Organisation https://www.ecco-ibd.eu/

    Mercaptopurine Therapy and TPMT and NUDT15 Genotype https://www.ncbi.nlm.nih.gov/books/NBK100660/

    Show more Show less
    26 mins

What listeners say about Medscape InDiscussion: Crohn's Disease

Average customer ratings
Overall
  • 5 out of 5 stars
  • 5 Stars
    1
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    0
  • 1 Stars
    0
Performance
  • 5 out of 5 stars
  • 5 Stars
    1
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    0
  • 1 Stars
    0
Story
  • 5 out of 5 stars
  • 5 Stars
    1
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    0
  • 1 Stars
    0

Reviews - Please select the tabs below to change the source of reviews.